Mounjaro, Wegovy users regain weight
Analysis based on 6 articles · First reported Mar 04, 2026 · Last updated Mar 05, 2026
The study's findings on significant weight regain after stopping Tirzepatide and Semaglutide could negatively impact the stock prices of companies producing these drugs, such as Eli_Lilly_and_Company and Novo_Nordisk. It may also lead to a re-evaluation of prescribing guidelines and patient expectations for long-term weight management solutions.
A new study by the University of Cambridge has revealed that individuals using obesity medications like Tirzepatide and Semaglutide are likely to regain almost two-thirds of the weight they lose within a year of stopping the drugs. While some weight loss may be sustained, researchers Brajan Budini and Steven Luo warn that if the regained weight is predominantly fat, patients could be 'worse off than before' they started treatment. The study, published in eClinicalMedicine, involved six trials with over 3,200 people and highlights inconsistencies in current prescribing guidelines for GLP-1 receptor agonists, which include Tirzepatide and Semaglutide. The United Kingdom — National Institute for Health and Care Research recommends a maximum two-year use for semaglutide (Semaglutide), but no such limit exists for tirzepatide (Tirzepatide). Researchers are calling for more trials to explore the effect of these drugs on body composition and for doctors to advise patients on diet and exercise to mitigate weight regain risks.
Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.
Open Dashboard